BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 24504521)

  • 1. Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas.
    Micci F; Panagopoulos I; Thorsen J; Davidson B; Tropé CG; Heim S
    PLoS Biol; 2014 Feb; 12(2):e1001784. PubMed ID: 24504521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma.
    Salzman J; Marinelli RJ; Wang PL; Green AE; Nielsen JS; Nelson BH; Drescher CW; Brown PO
    PLoS Biol; 2011 Sep; 9(9):e1001156. PubMed ID: 21949640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas.
    Agostini A; Brunetti M; Davidson B; Göran Tropé C; Heim S; Panagopoulos I; Micci F
    Int J Cancer; 2018 Sep; 143(6):1379-1387. PubMed ID: 29633253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of DPP9 in gene fusions in serous ovarian carcinoma.
    Smebye ML; Agostini A; Johannessen B; Thorsen J; Davidson B; Tropé CG; Heim S; Skotheim RI; Micci F
    BMC Cancer; 2017 Sep; 17(1):642. PubMed ID: 28893231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma.
    Kannan K; Coarfa C; Rajapakshe K; Hawkins SM; Matzuk MM; Milosavljevic A; Yen L
    PLoS Genet; 2014 Mar; 10(3):e1004216. PubMed ID: 24675677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes.
    Earp MA; Raghavan R; Li Q; Dai J; Winham SJ; Cunningham JM; Natanzon Y; Kalli KR; Hou X; Weroha SJ; Haluska P; Lawrenson K; Gayther SA; Wang C; Goode EL; Fridley BL
    Oncotarget; 2017 Jul; 8(29):46891-46899. PubMed ID: 28423358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression patterns in ovarian carcinomas.
    Schaner ME; Ross DT; Ciaravino G; Sorlie T; Troyanskaya O; Diehn M; Wang YC; Duran GE; Sikic TL; Caldeira S; Skomedal H; Tu IP; Hernandez-Boussard T; Johnson SW; O'Dwyer PJ; Fero MJ; Kristensen GB; Borresen-Dale AL; Hastie T; Tibshirani R; van de Rijn M; Teng NN; Longacre TA; Botstein D; Brown PO; Sikic BI
    Mol Biol Cell; 2003 Nov; 14(11):4376-86. PubMed ID: 12960427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.
    Shinmura K; Kageyama S; Tao H; Bunai T; Suzuki M; Kamo T; Takamochi K; Suzuki K; Tanahashi M; Niwa H; Ogawa H; Sugimura H
    Lung Cancer; 2008 Aug; 61(2):163-9. PubMed ID: 18242762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
    Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
    Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
    Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
    Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
    Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
    J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
    Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
    Wong DW; Leung EL; So KK; Tam IY; Sihoe AD; Cheng LC; Ho KK; Au JS; Chung LP; Pik Wong M;
    Cancer; 2009 Apr; 115(8):1723-33. PubMed ID: 19170230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.
    Mandai M; Konishi I; Koshiyama M; Mori T; Arao S; Tashiro H; Okamura H; Nomura H; Hiai H; Fukumoto M
    Cancer Res; 1994 Apr; 54(7):1825-30. PubMed ID: 7907945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
    Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
    Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
    Zhang X; Zhang S; Yang X; Yang J; Zhou Q; Yin L; An S; Lin J; Chen S; Xie Z; Zhu M; Zhang X; Wu YL
    Mol Cancer; 2010 Jul; 9():188. PubMed ID: 20624322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
    Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
    PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant Expression of Anaplastic Lymphoma Kinase in Ovarian Carcinoma Independent of Gene Rearrangement.
    Tang S; Yang F; Du X; Lu Y; Zhang L; Zhou X
    Int J Gynecol Pathol; 2016 Jul; 35(4):337-47. PubMed ID: 27271776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.